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Abstract
The term IORT (intraoperative radiotherapy) is currently used for various techniques that show huge differences in dose
delivery and coverage of the tissue at risk. The largest evidence for boost IORT preceding whole breast irradiation (WBI)
originates from intraoperative electron treatments (IOERT) with single doses around 10 Gy. At median follow-up
periods at 6 years, outstandingly low local recurrence rates of less than 1% are observed. Higher local relapse rates
were described for G3 tumors and triple negative breast cancers as well as for IORT following primary systemic
treatment for locally advanced tumors. Even there, long term (>5y) local tumor control rates mostly beyond 95% were
maintained. Compared to other boost methods, an intraoperative treatment has evident advantages in terms of
precision (by avoiding a “spatial and/or temporal miss”), cosmetic outcome and patient comfort. Direct visualisation of a
tumor bed during surgery guarantees for an accurate dose delivery, which has additionally gained importance in times
of primary reconstruction techniques after lumpectomy, since IORT is performed before breast tissue including parts of
the tumor bed is mobilized for plastic purposes. As a consequence of direct tissue exposure without distension by
hematoma/seroma, IORT allows for small treatment volumes and complete skin sparing, both having a positive effect
on late tissue tolerance and, hence, cosmetic appearance. Boost IORT marginally prolongs the surgical procedure, while
significantly shortening postoperative radiotherapy. Its combination with external beam radiotherapy to the whole
breast (WBI) is currently tested in two multicentric prospective trials: as kV-IORT in the multicentric TARGIT-B (oost)
study, and as IOERT in the HIOB trial (3 weeks hypofractionated WBI preceded by IORT electron boost).
Keywords: IORT, Intraoperative radiotherapy, IOERT, Boost, Electrons, Orthovoltage, Breast cancer, Tumor bed,
Cosmesis, hypofractionation
Introduction
In the Western World, breast cancer mortality rates have
declined since 1975, attributed to the increased use of
screening mammography and greater use of adjuvant treat-
ments, including radiotherapy. For locoregional treatment,
breast-conserving therapy is regarded as standard of care,
comprising breast conserving surgery followed by ipsilateral
whole-breast irradiation (WBI) as an integral component.
Postoperative radiotherapy significantly reduces local
recurrence rates. The more pronounced the achieved re-
duction, the more substantially it translates into improved
survival. Four prevented local recurrences result in one
avoided breast cancer death [1, 2].
Rationale for IORT and Biology of Single High Doses
Pathological analyses revealed that the greatest tumour
cell density (up to 90% of microscopic remainders) is
observed in an area of 4 cm surrounding the macroscopic
tumour edge [3, 4]. As a consequence, after a breast-
conserving operation, the tumor bed represents the region
with the highest probability of in-breast recurrence.
Therefore, an additional booster dose to the tumor bed
significantly reduces local recurrence rates [5]. Up to now,
these boosts are traditionally still applied mostly by exter-
nal beam electrons of 10–16 Gy (5–8 × 2 Gy) or, alterna-
tively, by interstitial implants (HDR-brachytherapy).
The idea of intraoperative irradiation (IORT) during
breast-conserving surgery is the delivery of a high single
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boost dose to the area at highest risk for subclinical
tumour cell contamination with utmost precision, due to
direct visualisation. The method was originally intro-
duced by the Medical College of Ohio (MCO) in Toledo,
Ohio, USA, and the Centre Regional de Lutte Contre Le
Cancer (CRLC) in Montpellier, France, based on reports
of 72 patients treated with an electron boost (intraopera-
tive electron radiotherapy (IOERT)) [6–8].
Compared to squamous cell carcinoma, breast cancer
seems to show a different sensitivity towards higher single
doses. In 1989, Fowler postulated an alpha/beta ratio of 4
for breast cancer as its best approximation instead of 10 for
most SCC [9]. This value was strongly supported by the
clinical outcome of Canadian and British Hypofractionation
Trials [10, 11]. A lower ratio results in higher sensitivity
against higher doses per fraction, an argument clearly in
favour of IORT. In the linear quadratic model, using an
alpha/beta value of 4, an IORT dose of 10 Gy amounts to a
BED of 35, hence, being isoeffective to a boost of about
24 Gy when applied in single fractional doses of 2 Gy.
However, the model was only tested for single doses below
15 Gy [12]. The prediction of isoeffects of doses above this
level leaves open questions and has to be further evaluated.
Beyond these dose-effect extrapolations, it was hypothe-
sized that immediate irradiation during surgery has implica-
tions on the tumor microenvironment abrogating the
proliferative cascade induced by surgical wound healing. In
vitro, wound fluid has been described to stimulate tumor
cell proliferation and invasion, which can be blocked by a
high-dose IORT [13, 14]. Another aspect is the prevention
of possible residual tumor cell repopulation between
surgery and adjuvant radiotherapy. Furthermore, a good
oxygenation status of the tumor bed during operation could
also be a factor for enhanced biological effectiveness, which
has not been investigated yet. All these cellular and trans-
cellular reactions of irradiated tissues are neither clarified in
detail nor understood in their particular impact on clono-
genic cell inactivation—and hence, local control—and are
subject of ongoing research [15–17].
IORT Treatment Techniques
In the late 1990s, a broad clinical IOERT application
started at the European Institute of Oncology (EIO) in
Milan, Italy, and the Paracelsus Medical University
(PMU) in Salzburg, Austria. Since then, IORT to the
tumor bed during breast-conserving surgery has be-
come a booming field of interest for partial breast ir-
radiation, either as an anticipated boost or as the sole
treatment strategy in limited-stage breast cancer.
This has given rise to the development of different tech-
nical approaches, with the term “IORT” now primarily used
for the following techniques: low-kV orthovolt systems
(e.g., Intrabeam) and intraoperative radiotherapy with elec-
trons on mobile or standard linear accelerators (IOERT).
The orthovolt systems consist of a miniature, electron
driven, low-kV energy X-ray source, emitting an isotropic
X-ray spectrum. For breast irradiations, spheric applica-
tors, chosen according to the excision cavity’s size, are put
at the top of the source, resulting in a spherical dose deliv-
ery with very steep dose fall-off.
Linac-Based IOERT is possible with various electron
energies (4–18 MeV). After tumour removal, the tissue
surrounding the excision cavity is surgically mobilised and
temporarily approximated by sutures in order to bring
adjacent walls into reach of the electron beam. The tissue
thickness is usually measured by intraoperative ultrasound
for individual depth dose prescription, choice of proper
electron energies, and electron tube diameters provid-
ing safe coverage of the tumour bed, respectively, build-
ing clear dosimetric and volumetric advantages in
comparison to the kV system The dosimetric properties
of the two IORT methods in terms of dose homogen-
eity, flexibility towards asymmetric target volume
shapes, and their consequent ability to deliver a speci-
fied minimum dose to a given volume differ tremen-
dously [18]. Hence, outcome analyses of local control
rates as well as cosmetic results after “IORT” must be
performed according to the used technique.
IORT Treatment Concepts: Boost versus Single
Modality
For both technical IORT approaches (electrons and
orthovolt), two different treatment concepts are proposed:
(1) IORT as full dose partial breast irradiation (PBI)
with either electrons (ELIOT) or orthovolt devices
(TARGIT);
(2) IORT as anticipated boost followed by whole-
breast radiotherapy (WBI) (BIO-boost = breast in-
traoperative boost).
Pros and cons of PBI strategies including application by
IORT are matter of ongoing debate [19–22]. Interpret-
ation of the so-far results following sole IORT—by any
means—to be isoeffective towards whole-breast treatment
strategies is premature, the respective trials show partially
conflicting results and, most important, median follow-up
periods below 4 years [22, 23]. True local recurrences,
however, are presumed to occur between 40 and
65 months after primary treatment [24, 25], out-quadrant
relapses even later than that [26] when WBI was per-
formed. Only adequate long term experience will reveal
the potential of a sole IORT approach to replace WBI in
selected patient groups. Therefore, this paper focuses on
results after Boost IORT, where the duration in follow-up
shows by far higher maturity, and is supplementing a pre-
vious publication [27].
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Boost IORT addresses the question of whether this ap-
proach is an effective and/or superior alternative to conven-
tional boost techniques. The advocates of a BIO-boost
emphasise the use of lower single doses compared with a
full-dose concept, with dose ranges well understood in
terms of tumour effects and late tissue reactions. Since
IORT is followed by WBI, the concept still accounts for the
(unknown) risk of occult tumour burden in distant quad-
rants. Therefore, it is less vulnerable to a possible underdo-
sage in the periphery of a tumour bed and—unlike PBI
concepts—remains applicable in every risk constellation.
Clinical Results
Boost IORT with Electrons (IOERT)
Despite its retrospective character, the International Society
of Intraoperative Radiotherapy (ISIORT) Europe pooled
analysis on IOERT provides the best available evidence so
far [28, 29].
The ISIORT Europe Pooled Analysis (BIO-Boost) [29]
The joint investigation evaluated the long-term outcome
of the IOERT strategy aimed at reducing local recurrence
in breast cancer and was carried out in a joint effort by
seven institutions from Austria, Germany, Italy, and Fran-
ce—all members of ISIORT’s European Group (ISIORT
Europe). Until October 2005, 1109 unselected patients of
any risk group have been identified among seven centers
using identical methods, sequencing, and dosage for intra-
and postoperative radiotherapy. A median IOERT dose of
10 Gy was applied (90% reference isodose), preceding WBI
with 50–54 Gy (single doses 1.7–2 Gy). 60% of all patients
presented with at least one of the following adverse prog-
nostic factors for local recurrence: tumour size > 2 cm,
high grade, age < 45 years, and positive lymph nodes. In
the most recent long-term analysis, at a median follow-up
of 72.4 months (0.8–239), only 16 in-breast recurrences
were observed, half of them accounting for true local
recurrences; this yields an in-breast tumour control rate of
99.2% at 73.3 months. Relapses occurred 12.5–151 months
after primary treatment. In a multivariate analysis, grade 3
tumour was found to be predictive of recurrence (p =
0.031). A significant univariate trend was found for in-
breast relapse in case of negative hormonal status and
young age (below 40 years). Annual in-breast recurrence
rates amounted to 0.64%, 0.34%, 0.21%, and 0.16% in pa-
tients <40 y; 40–49 y; 50–59 y, and ≥60 y, respectively. In
all risk subgroups, a 10 Gy IOERT boost prior to WBI pro-
vided local control rates which compare favourably to the
reported figures in all trials with similar length of follow-
up, irrespective of the used boost methods [5, 30–32].
To ascertain the role of a WBI delay following IOERT,
three time slots were considered: WBI onset <70 days,
>70 ≤ 140 days, and >140 days after IOERT, respectively.
Along these slots, no influence on LR rates could be
identified. Patients recurring showed a mean time gap be-
tween their IOERT and WBI of 7.5 weeks (range: 3.2–31.6).
Furthermore, in a retrospective matched-pair analysis,
188 patients with external e-boost (6 × 2 Gy Dmax (1.8 Gy
ref D)) were compared to the pooled analysis’ first 190 pa-
tients from Salzburg IOERT (10 Gy Dmax (9 Gy ref D))
[33]. At 10-year follow-up, the in-breast recurrence rate in
the external e-boost group was 7.2% and 1.6% in the
IOERT group, respectively. This significant difference was
almost entirely due to a reduction in true local recurrence.
Boost IORT with Low-Kilovoltage X-Rays
Compared to IOERT, clinical long term experience follow-
ing boost IORT with 50 kV X-rays is yet less solid, with
published updates of two larger cohorts available [34, 35].
In a multicenter pilot study prior to the international
Targit A-trial, the feasibility of 50 kV-IORT was tested
among participating institutions [34]. Between 1998 and
2005, 299 patients were treated with a 20 Gy IORT
boost (surface dose) during breast conserving surgery
(BCS), followed by 45–50 Gy WBI (2 Gy single fraction)
after wound healing or completion of adjuvant chemo-
therapy when indicated. After a median follow-up of
5 years, eight ipsilateral tumor recurrences were re-
ported, resulting in a recurrence rate estimate of 1.73%
(SE 0.77, Kaplan-Meier) and an observed rate of 2.67%,
respectively. The authors concluded that, for patients with
similar selection at risk for in-breast relapse, their findings
compared favorably to the tumor control rates achieved in
the EORTC boost trial [5] or the START-B trial [32].
A second series provides a single-center experience fol-
lowing kV-boosts with 18–20 Gy plus WBI (46–50 Gy/
2 Gy per fraction) [35]. A total of 197 patients were
treated, with the cohorts partially overlapping with the
multicenter study. The last update was published at a me-
dian follow-up period of 37 months. At this point of time,
six in-breast events were recorded (5 invasive, one in situ
relapse), accounting for a 3% in-breast recurrence rate
(both at 3 and at 5 years).
Compared to the results following IOERT, local recur-
rence rates look somewhat higher, despite similar patient
selection. In addition, sample sizes were significantly lower,
and follow-up was also less mature. However, a definitive
answer on the superiority of a respective IORT method
would necessitate a randomized trial. Indirect evidence on
the basis of observational head-to-head comparisons indi-
cates a trend in favor of IOERT. A possible explanation
might be the superior coverage of breast tissue by electrons,
where larger volumes of a putative tumor bed are treated
with uniformly high doses. Moreover, clinical target
volumes often appear asymmetric, which is better compen-
sated by IOERT in terms of spatial direction of dose depos-
ition (margin-directed applicator guidance) [18].
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Boost IOERT for the new “high risks”
Boost IOERT after Primary Systemic (Neoadjuvant)
Treatment
In patients with locally advanced breast cancer (LABC),
in-breast tumor recurrence rates (IBTR) are reported to
be increased after breast BCS following primary systemic
treatment (PST). To date, there are no publications on the
effect of an IOERT boost in these high-risk constellations.
In a retrospective analysis, a subgroup from the Salzburg
cohort was evaluated for subsequent IBTR following PST,
BCS, and IOERT preceding whole breast irradiation [36].
Eighty-three patients with clinical stage II or III breast
cancer treated between 2002 and 2007 were identified and
analysed in 2012. Patients received 3 to 6 cycles of anthra-
cycline/taxane containing preoperative chemotherapy. All
patients had breast conserving surgery with sentinel node
biopsy and axillary lymph node dissection and received
IOERT with 9 Gy to the 90% reference isodose as antici-
pated tumor bed boost. WBI was performed after surgery
for all patients with single fractional doses of 1.7–1.8 Gy
(5x/week) to total doses of 51–57 Gy.
Two patients refused WBI, leaving 81 patients for fur-
ther analysis. Pathologic complete response was achieved
in 14/81 (17%) patients. After a median follow-up of
59 months (range 3–115), two IBTR, both in the former
index quadrant, were observed, corresponding to a local
control rate (LC) of 98.5%. In this retrospective analysis,
boost IOERT turned out to be a highly effective tool for
the prevention of IBTR in LABC following neoadjuvant
chemotherapy, likewise to its demonstrated potential in
multimodal adjuvant regimen.
IOERT in triple-negative Breast Cancer
In a retrospective evaluation, survival and local control
rates of triple-negative breast cancer subtypes, treated
with breast-conserving surgery and boost IOERT followed
by WBI, were analysed [37]. Triple-negativity was subclas-
sified as five marker negative (5NP) and core basal (CB)
types, respectively. A total of 71 patients were enrolled,
chemotherapy was applied in a neoadjuvant (12%), adju-
vant (75%), or combinational setting (7%).
After a median follow-up of 97 months (range 4–
170 months), 5 in-breast recurrences were detected (7.0%).
For all patients, 8-year actuarial rates for local control,
metastases-free survival, disease-specific survival, and over-
all survival amounted to 89, 75, 80, and 69%, respectively.
All local recurrences occurred in grade 3 (G3) tumors irre-
spective of their specific immunohistochemical phenotype;
thus, the local control rate for grades 1/2 (G1/2) was 100%
for both 5NP and CB, while for G3 it was 88% for 5NP and
90% for CB (p = 0.65 and 0.82, respectively, n.s.). For
disease-specific survival, only the difference of the best-
prognosis group 5-NP/G3 vs. the worst-prognosis cohort
CB/G1/2 was statistically significant: 90% vs. 54% (p = 0.03).
In sum, in this prognostically impaired subgroup of
breast cancer patients. boost-IOERT also provided high
long-term in-breast control, comparing favourably with
results from non-IORT cohorts.
Toxicity and Cosmesis following Boost IORT
In all studies, IORT manoeuvres turned out to be safe and
feasible, showing no treatment related mortality or excess
acute local morbidity in terms of delayed wound healing or
infection rates compared to conventional treatment [6, 38–
40]. As to late reactions, cumulative incidences of fibrosis/
sclerosis within the IORT volumes were slightly different
according to the treatment concept: for boost patients,
tolerance was excellent with incidences of 20–25% G1-2
and less than 2% G3-reactions [6, 8, 41, 42]. Following full-
dose IORT, reported rates amounted up to 80% G1,
30% G2, and up to 6% G3-sequelae [43–45].
Cosmetic outcome after IORT boosts was analysed in
four reports altogether comprising roughly 500 patients. In
two smaller trials, no difference was described for the boost
patients in comparison to conventional groups: results were
rated as 86/91% to be good or excellent for IORT-Boosts
and 81/96% for the control groups, respectively [39, 41].
Longest-term experience is provided by Lemanski et al. [8]
who reported about late reactions in 42 recurrence-free pa-
tients after a median follow-up of 9 years following IOERT.
Six patients (14%) experienced Grade 2 late subcutaneous
fibrosis within the boost area. Overall cosmesis was scored
to be good to excellent. Based on their experience in 48 pa-
tients, Wenz et al. described inferior cosmetic results when
time intervals between orthovoltage IORT and onset of
WBI fall below 30 days [46].
In all these studies, the authors used different stan-
dardized cosmetic scoring systems based on qualitative
estimations. However, in comparison to conventional
techniques, no negative impacts on cosmesis following
IORT have been reported so far in any concept.
In the Salzburg Series, cosmetic long term results follow-
ing boost IOERT with 10 Gy, were evaluated in 403 pa-
tients by photo-documentation in four standardized
positions in order to provide reproducible examination
conditions [47]. Cosmetic outcome was assessed separately
by patients and treating physicians (surgeon and radiation
oncologist), respectively, within a 5-point-score as described
by Harris and van Limbergen. Patient-, tumor- and
treatment-related factors were analysed with regard to pos-
sible impact on the cosmetic result. For the whole cohort,
median time between end of radiotherapy and cosmetic
evaluation was 45 months; a separate subgroup analysis
was carried out for 261 patients with a minimum follow-up
of three years (median 56 months). For the whole cohort,
the patients’ self-assessments yielded around 93% “Satisfac-
tory” (Excellent/Good) and 98% “Acceptable” (Excellent/
Good/Moderate). These figures were almost identical to
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the scorings in the subgroup with longer follow up: 91%
satisfactory and 97% acceptable scorings, respectively.
Physicians’ evaluation revealed 64% satisfactory and 95%
acceptable results for both groups. Telangiectasia were not
described at all. A significant positive correlation was found
between physicians’ and patients’ evaluation. Age and appli-
cator diameter (possibly as surrogate for length of surgical
scar) had a significant negative impact on the cosmetic
outcome, whereas, for example, tumor-stage, grading,
electron-energy, and boost-volume had no significant
influence. IORT as a 10 Gy electron-boost within breast
conserving treatment shows in the longer follow-up excel-
lent cosmetic results. A negative impact of factors attribut-
able to IORT on the cosmetic outcome was not identified.
Ongoing Trials
TARGIT-B (oost)
In order to test the superiority of a TARGIT IORT boost
compared to an external- beam boost, the multicentric,
prospective, randomized TARGIT-B study was initiated.
More than 20 centers have already started recruiting,
and 1,800 young or high-risk patients will be included
[https://clinicaltrials.gov/ct2/show/NCT01792726].
HIOB Trial
Hypofractionated Whole-Breast Irradiation following Intra-
Operative Electron Boost. (http://www.clinicaltrials.gov/ct2/
show/NCT01343459?term=hiob&rank=1).
In an attempt to further reduce overall treatment dur-
ation without compromising local control rates, the multi-
centre HIOB trial was started in January 2011 as an
ISIORT investigator initiated study. In this trial, Boost
IOERT of 10 Gy is combined with hypofractionated WBI
(15 × 2.7 Gy) for stage I/II breast cancer. A similar concept
of IOERT plus short-term WBRT was tested in a phase II
design by the Milano Group [38]. In the HIOB trial, an-
nual in-breast recurrence rates are defined as benchmarks
for successful treatment. Superiority of the intervention is
given by falling below the best published evidence in non-
IORT cohorts. Beside tumor-related endpoints, major em-
phasis is made on cosmetic outcome. This study is still
recruiting, a last interim analysis on early results is avail-
able by August 2014 [48].
At this point of time, 645 patients have been recruited
within ten active institutions, 481 of them already in fol-
low- up. For IOERT, the median energy chosen was
7 MeV (range 4–12) with median tube diameters of 6 cm
(4–8) and mean prescription depths of 19 mm (6.2 SD),
resulting in mean D90 volumes of 19 ml. Perioperatively,
no major complications were observed. Four weeks after
the end of WBI and 479 evaluated patients, 177 (37%)
showed no reactions (CTC 0), 277 (58%) presented with
faint (CTC 1) and 24 (5%) with moderate to brisk ery-
thema (CTC 2), respectively. G0-I late reactions (LENT-
SOMA) occurred in a mean frequency of 97%, 96%, 98%
and 96% after 4–5 months,1,2 and 3 years follow-up,
respectively. Cosmesis was assessed postoperatively by pa-
tients themselves (subjective) and doctors (objective).
Baseline appearance was first assessed after wound healing
prior to WBI and scored as sufficient (excellent and good)
in 69%/74% of 614 subjective/447 objective evaluations.
Respective results at 4–5 months, one, two and three years
post RT were 87%/75% of 418/378, 89%/77% of 306/164,
83%/75% of 132/107 and 84%/87.5% of 31/24 ratings. At a
median follow-up period of 12.6 months (range 0.5-37),
three patients were metastasized, two have died, and no
in-breast recurrence was noted yet.
In sum, tolerance of a combined IOERT/hypofractio-
nated WBI regimen was excellent, acute reactions mod-
erate, and late reactions insignificant in short-term
assessment. With regard to postoperative appearance,
early cosmetic results are not impaired by this regimen.
Both tumor control and cosmetic outcome have to be
evaluated on long-term follow-up.
Conclusion
The term IORT is currently used for various techniques,
which show decisive differences in dose delivery. To
date, all publications on boost IORT for conservatively
operated breast cancer report about outstandingly low
local recurrence rates in almost all risk settings, with the
maturest evidence for electron based treatments
(IOERT). These facts are interpreted as a consequence
of utmost precision in dose delivery, and hypothesized
to be biologically superior to conventional boosts due to
avoidance of geometric and temporal miss, and possibly
also due to abrogating the proliferative cytokine cascade
induced by surgical wound healing. In addition, IORT
allows for small treatment volumes and complete skin
sparing, both having positive impact on late tissue
tolerance and hence, cosmesis. Last, in terms of patient
comfort, IORT prolongs the surgical procedure only in a
small degree, while drastically shortening - or in selected
cases maybe even replacing - postoperative radiotherapy.
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